Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
Trial details
- Registry ID
- NCT04525157
- Phase
- Phase 2
The FDA approved Afamelanotide on 8 Oct 2019.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)NCT04525157 | Clinuvel Pharmaceuticals Limited | Phase 2 | Completed | 2016-02-02Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2019-10-08Day | Afamelanotide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA210797", "applicant_as_listed_by_fda": "CLIVUNEL INC", "brand_names": ["SCENESSE"], "active_ingredients": ["AFAMELANOTIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20191008", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |